HIGHLIGHTS
- who: Zijun Ma and colleagues from the Sinopharm Dongfeng General Hospital, Hubei University of Medicine, Daling Road, Shiyan, Hubei, China have published the article: Research Progress on the GIP/GLP-1 Receptor Coagonist Tirzepatide, a Rising Star in Type 2 Diabetes, in the Journal: Journal of Diabetes Research of 15/04/2023
- what: Based on preclinical studies and clinical trials the aim of this article is to discuss the latest clinical developments in tirzepatide to focus on its differences with other incretin therapies and to suggest future possibilities and mechanisms of tirzepatide therapy. Controlling hyperglycemia . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.